视网膜静脉阻塞激光光凝的时机选择

目的：观察激光光凝治疗不同病程的视网膜静脉阻塞(retinal vein occlusion,RVO)的临床疗效,探讨RVO激光光凝治疗的时机,为临床选择RVO光凝治疗时机提供依据。

方法：回顾性分析视网膜激光光凝治疗的RVO患者103例103眼,按发病时间将患者分为3组, A组46眼,病程≤1mo,其中视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)28眼,视网膜中央静脉阻塞(central retinal vein occlusion,CRVO)18眼; 缺血型RVO 30眼,非缺血型RVO 16眼。B组38眼,1mo<病程<3mo,其中BRVO 22眼,CRVO 16眼; 缺血型RVO 26眼,非缺血型RVO 12眼。C组19眼,病程≥3mo,其中BRVO 7眼,CRVO 12眼; 缺血型RVO 15眼,非缺血型RVO 4眼。随访3mo,观察光凝治疗后各组患者的视力变化差异、视网膜出血、眼部新生血管、黄斑中心凹厚度下降值。

结果：不同病程RVO光凝治疗后患者的最佳矫正视力提高率,视网膜出血、黄斑水肿吸收情况,黄斑中心凹厚度降低量,早期组优于晚期组,非缺血型RVO优于缺血型RVO,激光光凝治疗效果BRVO优于CRVO且差异具有统计学意义(P<0.05)。

结论：RVO早期激光光凝干预治疗,可以加速视网膜出血、黄斑水肿吸收,有效保护患者现有视力、促进远期视力提高,具有一定临床实用意义。     

视网膜静脉阻塞荧光素眼底血管造影观察

目的观察视网膜静脉阻塞（RVO）的荧光素眼底血管造影（FFA）的图像特征,加深对RVO病变的认识,探讨FFA在RVO的应用。方法对我院自2006年1月至2009年12月经临床诊断为视网膜中央静脉阻塞（CRVO）和视网膜分支静脉阻塞（BRVO）患者298例（298只眼）的FFA检查结果进行回顾性分析。结果 RVO患者共298例（298只眼）。CRVO者97只眼,占32.55%;BRVO者201只眼,占67.45%。其中颞上分支静脉阻塞117只眼,占分支静脉阻塞的58.21%;半侧静脉阻塞12只眼,占5.97%。有视网膜新生血管形成32只眼,占10.74%;黄斑囊样水肿者104只眼,占35.14%;视网膜毛细血管无灌注区形成者139只眼,占46.64%。78.86%的病例发病年龄在50岁以上。结论 BRVO发病率高于CRVO;BRVO中以颞上分支静脉阻塞最常见;视网膜新生血管形成和黄斑囊样水肿是RVO的两个主要并发症。FFA对RVO的诊断、分类分型、指导治疗有重要的意义。     

视网膜静脉阻塞与凝血因子Ⅻ的相关研究

目的 通过观察视网膜静脉阻塞患者静脉血中凝血因子Ⅻ(FⅫ)的活性,研究它与视网膜静脉阻塞(RVO)是否相关.方法 以随机方式收集我院门诊眼科常规检查眼底正常的正常人25例(25只眼),RVO患者25例(25只眼),按RVO发病年龄分为≤50岁和>50岁两组,根据RVO位置,将RVO病例组分为视网膜中央静脉阻塞(CRVO)、视网膜半侧静脉阻塞(HRVO)、视网膜分枝静脉阻塞(BRVO)三型.所有研究对象均在空腹抽取静脉血2.7 ml,一期法测定FⅫ活性,常规测定凝血功能(APTT).统计学方法采用Spss13.0软件包,对两组资料采用(Fisher-test)检验与t检验.结果 两组资料特征差异(年龄、性别)统计学上无显著性差异(P>0.05);试验组的FⅫ缺乏发生率虽然比对照组高,但两组比较统计学上差异无显著性(P=0.12),试验组的APTT低于对照组,两组比较统计学上差异有显著性(P=0.02).结论 本研究进一步证实了易栓危险因素(凝血因子Ⅻ)的缺乏与视网膜静脉阻塞的发生、发展之间存在内在的相关性.     

双眼视网膜静脉阻塞

报告23例双眼视网膜静脉阻塞，占同期收治视网膜静脉阻塞病例的5.85%.其中男性18例，女性5例，平均年龄55.4岁．双眼视网膜中央静脉阻塞(CRVO)2例；1眼CRVO，另1眼视网膜半侧静脉阻塞(HRVO)2例；1眼CRVO，另1眼视网膜分支静脉阻塞(BRVO)6例；双眼BRVOl3例。中央和视网膜半侧静脉阻塞14眼，分支静脉阻塞32眼．缺血型19眼，占41%；非缺血型27眼，占59%。双眼发病间隔平均3年零5个月。双眼与单眼发病的危险因素比，统计学差异无显著性。 （中华眼底病杂志，1994，10：174-175）     

炎症及动脉硬化相关因子与视网膜静脉阻塞的相关性

目的：研究视网膜静脉阻塞(RVO)患者血清白介素6(IL-6)、脂联素(ADPN)、Apelin、超敏C反应蛋白(hs-CRP)、血管内皮生长因子(VEGF)水平变化情况,从分子角度探究其与RVO的相关性。

方法：收集中央型视网膜静脉阻塞(CRVO)35例,分支型视网膜静脉阻塞(BRVO)37例为试验组1、2,年龄相关性白内障患者32例为对照组,记录其发病时间、视力、心脑血管疾病病史及OCT示黄斑水肿高度,酶联免疫吸附法检测其外周血血清中与炎症及动脉硬化紧密相关因子—IL-6、ADPN、Apelin、hs-CRP、VEGF的表达情况。

结果：BRVO组、CRVO组Apelin值分别为6.69(4.25,10.52)、7.12(3.78,8.58)ng/mL,均高于对照组1.19(0.74,1.49)ng/mL(P<0.05)。BRVO组、CRVO组ADPN值分别为8.06(4.67,10.81)、9.74(4.10,11.67)μg/mL。BRVO组、CRVO组IL-6值分别为35.89(17.63,37.50)、37.16(11.52,42.80)pg/mL。BRVO组、CRVO组hs-CRP值分别为161.10(54.51,164.01)、206.93(51.47,331.29)μg/mL。BRVO组、CRVO组VEGF值分别为158.25(82.24,230.41)、174.14(76.04,243.98)pg/mL。该四项因子试验组与对照组比较均无差异(P>0.05)。RVO组视力及黄斑水肿高度与上述血清因子水平未见明显相关。

结论：RVO患者Apelin增高,且Apelin可能为RVO发生的相关危险因素。ADPN、IL-6、hs-CRP、VEGF在RVO急性期未见特异性表达。     

放射状视神经切开术治疗缺血型视网膜中央静脉阻塞合并黄斑水肿的疗效观察

目的 观察放射状视神经切开术(RON)治疗缺血型视网膜中央静脉阻塞(CRVO)合并黄斑水肿的效果。 方法 回顾分析6例缺血型CRVO合并黄斑水肿患者行玻璃体切割联合RON治疗的临床资料，对比观察患者手术前后视力、荧光素眼底血管造影(FFA)、光相干断层扫描(OCT)检查结果,重点观察黄斑厚度、视网膜静脉充盈、视网膜出血和视盘水肿的改善情况。 结果 6例患者手术后视力均有不同程度提高，视网膜出血明显减少，5例患者黄斑水肿不同程度改善，4例患者视网膜静脉扩张改善，2例合并视盘水肿的患者手术后视盘水肿消失。 结论 RON能够改善缺血型CRVO合并的黄斑水肿，但不能排除治疗效果和玻璃体切割手术有关。(中华眼底病杂志,2005,21:3-5)     

研究人员和阅片中心人员对视网膜静脉阻塞分类的一致性（SCORE研究报告2）[英]

SCORE（The Standard Care versus COrticosteroid in REtinal Vein Occlusion）研究系常规疗法和皮质类固醇治疗视网膜静脉阻塞的对比研究。它包括两个Ⅲ期多中心随机临床试验，用以评价玻璃体内注射曲安奈德的有效性和安全性。其中一个试验以视网膜中央静脉阻塞（CRVO）患者为对象，另一个以视网膜分支静脉阻塞（BRVO）患者为对象，并将半侧视网膜静脉阻塞（HRVO）患者归入BRVO试验组。因CRVO组和BRVO组间的常规治疗方法不同，故对患者进行正确分类是使试验具有良好针对性的保证。     

视网膜电图明视负向反应在视网膜静脉阻塞中的变化

目的 观察视网膜静脉阻塞(RVO)患者视网膜电图(ERG)明视负向反应(PhNR)的变化特点.方法 对间接检眼镜、荧光素眼底血管造影(FFA)检查确诊的RVO患者30例30只患眼以及对侧健康眼进行视力、视野、闪光ERG(FERG)检查,同时选取与其性别、年龄相匹配的正常人25例50只眼作为正常组进行FERG检查.所有检查均按常规方法进行.RVO患者中,视网膜中央静脉阻塞(CRVO)患者14例14只眼、视网膜分支静脉阻塞(BRVO)患者16例16只眼.根据其病史及FFA检查结果,将其按病程时间划分为小于1个月、1～3个月、大于3个月组;另外再根据RVO分型标准及具体检查结果,将RVO患者分为缺血型和非缺血型.对比分析RVO患眼与对侧健康眼以及正常眼PhNR振幅变化及ERG其他参数指标,包括振荡电位(Ops),视锥细胞反应(Cone-a、Cone-b),视杆细胞反应(Rod-b),暗适应眼的最大反应(Max-a、Max-b),30 Hz闪烁光反应(30 Hz)的差异以及PhNR振幅变化与RVO疾病缺血类型、病程的关系.结果 PhNR振幅在CRVO患眼为(28.20±5.80)μV,BRVO患眼为(36.96±4.71)μV,对侧健眼为(61.25±3.93)μV,正常眼为(59.33±16.92)μV.CRVO组与对侧健眼、正常组比较,差异有统计学意义(F=10.69,9.80;P＜0.001),BRVO组与对侧健眼、正常组比较,差异有统计学意义(F=9.69,9.75;P＜0.001).CRVO组中缺血型PhNR值为(22.77±5.73)μV,非缺血型为(36.63±12.91)μV,二者差异有统计学意义(t=6.54,P＜0.01);BRVO组缺血型PhNR值为(32.39±13.22)μV,非缺血型为(46.73±10.43)μV,二者差异无统计学意义(t=2.12,P＜0.05);病程小于1个月组CRVO与BRVO分别为(24.58±4.60)、(27.94±15.73)μV,1～3个月组分别为(50.39±13.80)、(58.69±12.43)μV,大于3个月组为(25.40±19.94)、(34.48±16.72)μV,CRVO中1～3个月组与大于3个月组差异有统计学意义(F=4.30,P＜0.01).结论 RVO患眼的PhNR振幅较对侧健康眼以及正常对照眼明显降低,缺血型较非缺血型降低,随病程变化呈现下降、上升、下降的变化趋势.     

眼压和眼轴长与视网膜静脉阻塞的关系

目的探讨眼压和眼轴长与视网膜静脉阻塞（RVO）的关系。方法应用CanonTX-F型眼压计对56例RVO患者的眼压进行测量,并用A超对其眼轴进行测量,对照组为年龄、性别相匹配的98例白内障摘除患者。结果视网膜中央静脉阻塞（CRVO）阻塞眼眼压显著低于对测眼及正常对照眼（P〈0.01）;视网膜分支静脉阻塞（BRVO）阻塞眼眼压与对测眼及正常对照眼比较差异无显著性（P〉0.05）。CRVO阻塞眼眼轴长与对照眼比较差异有显著性（P〈0.01）;BRVO阻塞眼眼轴长与对照眼比较差异无显著性（P〉0.05）。结论眼轴长偏短是CR-VO的危险因素,CRVO可引起眼压降低;眼轴长偏短不是BRVO的危险因素,BRVO不能引起眼压降低。     

雷珠单抗治疗视网膜静脉阻塞的临床研究

目的 观察玻璃体内注射雷珠单抗(Ranibizumab)联合视网膜激光光凝治疗合并黄斑水肿的视网膜静脉阻塞(retinal vein occlusion,RVO)的疗效.方法 2013年10月至2015年3月我院确诊为RVO患者32例35眼纳入研究,分为视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)组18例(19眼)、视网膜中央静脉阻塞(cranch retinal vein occlusion,CRVO)组14例(16眼).所有患者均接受Ranibizumab玻璃体内注射,采用1+PRN方案.在初次注射后0.5～1个月,联合视网膜激光光凝治疗.比较两组患者治疗前、治疗后患眼黄斑中心视网膜厚度(macular central retinal thickness,CRT)、国际标准糖尿病早期治疗研究(Early treatment diabetic retinopathy study,ETDRS)视力表、裂隙灯、眼底镜、眼压以及眼底荧光血管造影检查(fluorescein fundus angiography,FFA).结果 随访2～6个月,平均4个月.CRVO组、BRVO组重复注射Ranibizumab的次数分别为(1.83±0.83)次、(1.58±0.67)次.CRVO组、BRVO组治疗前后ETDRS视力比较差异均有统计学意义(t=3.237、6.178,均为P＜0.05),CRVO组、BRVO组治疗前后CRT差异均有统计学意义(t=3.165、3.598,均为P＜O.05).两组术后CRT与年龄、糖尿病、高血压因素均无相关性(r =0.114、0.435、0.028、0.269、0.171、0.062,均为P＞0.05).BRVO组术前CRT及注射次数有相关性(r =0.556,P≤0.05).结论 经玻璃体内注射Ranibizumab联合视网膜激光光凝治疗RVO能促进出血吸收、改善黄斑水肿并且提高视力.两组末次随访CRT与年龄、合并糖尿病、合并高血压因素均无相关性.BRVO组研究结果显示IVR联合视网膜激光治疗疗效优于IVR单项治疗.     

Clinical characteristics of retinal venous occlusions occurring at different sites

AIMS: To identify the contributory factors associated with different sites of occlusion and the presence or absence of optic nerve head swelling (ONHS). METHODS: 874 cases of retinal venous occlusion (RVO) were prospectively examined at a tertiary referral centre and classified according to three defined sites of occlusion: arteriovenous crossing RVO (AV-RVO); optic cup RVO (OC-RVO); and optic nerve sited RVO. Optic nerve sited RVOs were further divided on the basis of presence (ONHS-RVO) and absence (NONHS-RVO) of ONHS. RVOs not occurring at any of the defined sites were grouped as no-site RVO (NS-RVO). Important clinical parameters were compared among four of the five subgroups by multivariate analysis of variance and chi(2) test (NS-RVO excluded). RESULTS: The overall multivariate analysis of variance for differences in the mean age, systolic and diastolic blood pressure, body mass index, and intraocular pressure (IOP) among the four subgroups were highly significant (p <0.0001). The F ratios indicated that the differences in the mean age and IOP accounted for this statistical trend. The mean age was statistically significantly lower in the ONHS-RVO group compared to the rest of the groups (p <0.0001). The mean age was significantly higher in OC-RVO compared to the AV-RVO group (p <0.05). The mean IOP was significantly higher in OC-RVO than in the rest of the groups (p <0.01 to 0.0001), while it was also higher in the NONHS-RVO group compared to the ONHS-RVO and AV-RVO groups (p <0.0001). The prevalence of primary open angle glaucoma (POAG), sex, laterality, involvement of the fellow eye, smoking and hypertension were compared by chi(2) tests. POAG was significantly more prevalent in the OC-RVO group than in the rest of the groups (p <0.0083), while it was also significantly more prevalent in the NONHS-RVO group compared to AV-RVO or ONHS-RVO (p <0.0083) groups. Smoking was significantly more prevalent in AV-RVO than in the rest of the groups (p <0.05). The proportion of male sex was significantly higher in ONHS-RVO compared to the AV-RVO group (p <0.05). Hypertension was significantly more prevalent in the AV-RVO than in the ONHS-RVO or NONHS-RVO groups (p <0.05). CONCLUSION: A new classification of RVO based on the site of occlusion and ONHS has been evaluated. The higher prevalence of hypertension and smoking in AV-RVO suggests a particular importance of cardiovascular risk factors in this group. The association of POAG with CRVO has been confirmed, but only for those cases without ONHS. A distinctive relation between raised IOP and OC-RVO has been demonstrated, suggesting a causal association. RVOs with ONHS tend to occur in younger people, with a higher proportion of males, and a lower prevalence of hypertension and POAG, suggesting that other causal factors may be important in this group. The new scheme resolves the confusion in the literature regarding classification of RVO, and has diagnostic, causal, prognostic, and therapeutic implications.     

玻璃体手术和眼内光凝治疗伴玻璃体积血和新生血管膜的视网膜静脉阻塞

目的评估玻璃体手术和眼内光凝治疗伴玻璃体积血、新生血管膜或牵拉性视网膜脱离的视网膜静脉阻塞（ｒｅｔｉｎａｌｖｅｉｎｏｃｃｌｕｓｉｏｎ，ＲＶＯ）的疗效。方法复习连续的３７例ＲＶＯ患者经玻璃体手术和眼内光凝治疗的３８只眼临床资料。视网膜分支静脉阻塞（ｂｒａｎｃｈｒｅｔｉｎａｌｖｅｉｎｏｃｃｌｕｓｉｏｎ，ＢＲＶＯ）１９例２０只眼，视网膜中央静脉阻塞（ｃｅｎｔｒａｌｒｅｔｉｎａｌｖｅｉｎｏｃｃｌｕｓｉｏｎ，ＣＲＶＯ）１８例１８只眼。结果手术中确认２７只眼有新生血管膜，２３只眼有牵拉性视网膜脱离。手术后３４只眼视力改善，占８９．５％，其中２２只眼有０．１以上的视力。４只眼视力未变。ＣＲＶＯ组病史较长，手术后视力改善较少。结论玻璃体手术和眼内光凝能改善多数伴有玻璃体积血、新生血管膜和牵拉性视网膜脱离的ＲＶＯ眼预后。     

视网膜静脉阻塞的多焦振荡电位

目的 探讨多焦振荡电位(multifocal oscillatory potentials, MOPs)在视网膜静脉阻塞中的临床应用价值。 方法 应用VERIS 4.0视诱发反应图像系统检测视网膜静脉阻塞患者19例19只眼，其中视网膜中央静脉阻塞(central retinal vein occlusion, CRVO)8例8只眼，视网膜分支静脉阻塞(branch retinal vein occlusion, BRVO)11例11只眼。20例正常人作为本组患者的正常对照组。放大器通频带的低频截止为100 Hz，高频截止为1 000 Hz。检测试野的水平视角为±26.6°，垂直视角为±22.1°，于4 min(分8段)记录103个六边形的视网膜反应。 结果 无论在整个测试区或分成五个环，正常眼的一阶反应于37 ms内，二阶反应的第一部分于47 ms内可见三个振荡电位OP-1，OP-2，OP-3，二阶反应振荡波形较一阶反应更明确。视网膜中央静脉阻塞和视网膜分支静脉阻塞患者有91.6%(66/72)的OP-1，OP-2和OP-3潜伏期较正常的延迟，68.1%(49/72) 的OP-1，OP-2和OP振幅较正常的降低，视网膜中央静脉阻塞较视网膜分支静脉阻塞的改变更明显。 结论 MOPs能有效和定量评价视网膜静脉阻塞患者不同区域的视网膜功能。 （中华眼底病杂志，2002，18：20-22）     

Differences in contributory factors among hemicentral, central, and branch retinal vein occlusions

Hemicentral retinal vein occlusion (HRVO) is an anatomic variant of central retinal vein occlusion (CRVO) and thus different from branch retinal vein occlusion (BRVO). Therefore, the risk factors for HRVO should be similar to those of CRVO and different from those of BRVO. To test this, the authors compared 15 demographic and clinical variables of 28 HRVO patients with those of 117 CRVO and 214 BRVO patients. Mean age of onset and sex ratio were not significantly different among the groups. Elevated erythrocyte sedimentation rate (ESR) (P = 0.019) and elevated intraocular pressure (IOP) (P = 0.025) were significantly more prevalent in the HRVO than the BRVO group. In addition, when the authors compared CRVO with BRVO, elevated ESR (P = 0.003), elevated IOP (P = 0.015), and positive purified protein derivative (PPD) (P = 0.003) were significantly more prevalent in the CRVO than the BRVO group, whereas hypertension (P = 0.03) and hyperopia (P = 0.008) were significantly more prevalent in the BRVO group. However, of the variables tested between HRVO and CRVO patients, no significant differences were found.     

单眼视网膜静脉阻塞患者对侧眼黄斑区血流密度和中心凹无血管区面积观察

目的:观察单眼视网膜静脉阻塞(RVO)患者对侧眼黄斑区血流密度和黄斑中心凹无血管区(FAZ)面积。方法:回顾性病例对照研究。2018年5~11月在长沙爱尔眼科医院临床确诊为单眼RVO的78例患者78只对侧眼纳入研究。其中,男性44例,女性34例;平均年龄(53.17±10.12)岁。视网膜中央静脉阻塞(CRVO)42例(CRVO组),视网膜分支静脉阻塞(BRVO)36例(BRVO组)。选取年龄和性别与RVO患者相匹配的33名正常健康者42只眼作为对照组。其中,男性17例22只眼,女性16例20只眼;平均年龄(53.48±10.84)岁。3组受检眼均行OCT血管成像检查,以仪器自带软件自动识别以黄斑中心凹为中心的直径6 mm区域及FAZ,自动测量黄斑区浅层和深层血流密度及FAZ面积。对比分析3组受检眼黄斑区浅层、深层血流密度和FAZ面积。结果:与对照组比较,CRVO组(t=-4.26、-4.93)、BRVO组(t=-4.79、-4.74)受检眼黄斑区浅层及深层血流密度均降低,差异均有统计学意义(P<0.05)。CRVO组、BRVO组受检眼黄斑区浅层及深层血流密度降低幅度分别为4.13%、5.51%及3.50%、4.58%,深层血流密度的降低幅度较浅层更大。CRVO组受检眼FAZ面积较对照组减小,差异有统计学意义(t=-3.43,P<0.05)。BRVO组与对照组受检眼FAZ面积比较,差异无统计学意义(t=-0.10,P>0.05)。结论:单眼RVO患者对侧眼黄斑区血流密度较正常健康眼降低,黄斑区深层血流密度的降低幅度较浅层更大。与正常健康眼比较,单眼CRVO患者对侧眼FAZ面积减小,单眼BRVO患者对侧眼FAZ面积无明显变化。     

Axial length and hyperopia in eyes with retinal vein occlusions

We performed a prospective study in order to elucidate thepredisposing role of axial length and hyperopia in retinal veinocclusions. The study group comprised 39 patients with unilateralcentral retinal vein occlusion (CRVO), 50 patients with unilateralbranch retinal vein occlusion (BRVO), 13 patients with unilateralhemispheric retinal vein occlusion (HRVO) and 45 controleyes.The axial length of affected eyes was compared to fellow eyesand control eyes in each subgroup of patients with retinal veinocclusion. No statistical difference was noted for any of thesubgroups (p > 0.05). Hyperopia was detected in 12 of 39 eyes(31%) with CRVO, 14 of 50 eyes (28%) with BRVO, 4 of 13 eyes(31%) with HRVO and 15 of 45 eyes (33%) in the control group.No statistically significant difference was discovered (p> 0.05).In the light of our study, we believe that axial length andhyperopia may not be risk factors in retinal vein occlusions, incontrast to common belief.     

视网膜中央静脉阻塞并发渗出性视网膜脱离的临床特征

目的探讨视网膜中央静脉阻塞并发渗出性视网膜脱离患者的临床特征.方法回顾性分析视网膜中央静脉阻塞并发渗出性视网膜脱离患者的一般情况及视力、眼压、眼底、荧光素眼底血管造影、眼部超声波等检查资料.结果15例患者中,男性8例,女性7例;年龄18～42岁,平均25岁.5例合并新生血管性青光眼.患者就诊时的视力：光感至0.05.眼底检查显示全视网膜散在出血、视网膜静脉迂曲,黄斑区有明显的水肿和出血,在水肿和脱离区的边缘可见大片渗出.坐位时视网膜脱离为2～5个钟点范围.全部患者均未见视乳头血管吻合支的形成.荧光素眼底血管造影显示大片出血遮蔽荧光或可见后极部毛细血管无灌注区.超声波测量有5只眼平均眼轴长为22.98 mm.结论渗出性视网膜脱离是视网膜中央静脉阻塞的少见、严重并发症.多见于青年患者,易并发新生血管性青光眼,其眼底及荧光素眼底血管造影检查具有特征性.     

Long-term real-world outcomes in retinal vein occlusions: How close are we to the trials?

Purpose:To assess and analyze the visual outcomes of patients with retinal vein occlusions in a real-world setting with a long-term follow-up of more than 5 years.Methods:Retrospective analysis of 56 patients having retinal vein occlusions from a tertiary eye center, with a mean follow-up of 7 years was performed. Primary outcome measures were mean change in best-corrected visual acuity (BCVA) from baseline at 6 months, 1 year, 2 years, 3 years, and final visit (≥5 years), proportion of patients having BCVA better than 20/40 and worse than 20/200, and mean number of injections. Secondary outcome measures were change in central macular thickness (CMT), development of subsequent retinal vein occlusion (RVO) in same eye or the other eye, and development of neovascular complications.Results:The mean change in letter score was + 11.84 in branch RVO (BRVO), +7.14 in non-ischemic central RVO (CRVO), and −9.5 in ischemic CRVO at 1 year, which changed to + 8.57, −5 and − 24, respectively, at the end of follow-up. CMT had improved from 506 ± 98.8 µm, 576.44 ± 149 µm, and 618 ± 178.27 µm, respectively, at baseline to 267 ± 94 µm, 345.20 ± 122.61 µm, and 265.50 ± 107.75 µm, respectively, in BRVO, non-ischemic, and ischemic hemi RVO (HRVO)/CRVO groups. The total mean number of injections given in BRVO, non-ischemic CRVO, and ischemic CRVO groups were 4.6, 6.6, and 4.1, respectively. None of the patients with BRVO developed neovascular glaucoma (NVG). Non-ischemic to ischemic HRVO/CRVO conversion was noted in 4/11 eyes at a mean duration of 12.6 months. NVG was noted in 7/9 eyes (77.8%) in initial ischemic CRVO/HRVO group and 3/4 (75%) converted eyes.Conclusion:Patients with BRVO have good visual outcomes with anti-VEGF, while in CRVO results may vary considerably owing to patient compliance and treatment burden on long-term follow-up in a real-world setting.